Collaborations & Alliances

Eisai, Gilead Enter Exclusive Agreement for JAK Inhibitor Filgotinib in Asia

Eisai obtains exclusive marketing right for filgotinib in South Korea, Taiwan, Hong Kong and Singapore and will take over manufacturing and marketing.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Eisai Co., Ltd. entered into an agreement with Gilead Sciences, Inc. for the commercialization and distribution of filgotinib (Jyseleca), an oral, JAK1 preferential inhibitor for indications of rheumatoid arthritis (RA), ulcerative colitis, and Crohn’s disease in Asia (South Korea, Taiwan, Hong Kong and Singapore). In December 2019, Eisai signed a partnership agreement with Gilead Sciences K.K., a Japanese subsidiary of Gilead, for the distribution and co-promotion of filgotinib in Japan. ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters